Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer
March 22, 2018
Origenis GmbH, a Germanbiotech company specializing in the discovery and development of highly selective small molecule kinase inhibitors for CNS disorders, today announced the appointment of Dr. Peter Seufer-Wasserthalas Chief Business Officer.Dr. Seufer-Wasserthal brings25 years experience in technology oriented business developmentto the company.
Prior to joining Origenis, he served asVice President Business Development at Intrexon Corporation(NYSE:XON)and before that held severalsenior executive and business development positions at Codexis, Inc., (NASDAQ:CDXS), where he closed numerous licensing, research andsupply agreements. Before Codexis, Dr. Seufer-Wasserthal managed a broad range of drug discovery collaborations, licensed pre-clinical candidates to Pharma partners and directedseveral drug development projects in theposition ofSenior Vice President of Business Development at Morphochem and Evotec.
He holds a Ph.D. in organic chemistry from the Technical University of Graz.Origenis ́CEO Michael Almstetter welcomed Dr. Seufer-Wasserthal: “We are excited to have Peter join at this stage of our growth. Beyond our focus on highly selective small molecule kinase inhibitors for CNS disorders, Origenis has developed a comprehensive set of non-CNS and ophthalmological assets that are validated by several Pharma partnerships and have the potential to significantly contribute to the company's top line.Peter will lead Origenis ́business activities and grow our relationships in the pharmaceutical market to establish additional collaborations with leading companies in the field.
I am confident that his deep industry insight and proven closing capabilities will be a tremendous asset to Origenis.